Introduction
============

Antimicrobial resistance has been the major problem for treating patients in the ICU. Most international guidelines are based on antimicrobial resistance rates observed in the USA. For an empirical antimicrobial decision strategy it is important to know the differences between local and imported data.

Objective
=========

To compare local ICU antimicrobial resistance rates (RJ-ICU) with USA-ICU antimicrobial resistance rates (USA-ICU).

Methods
=======

A prospective analysis of antimicrobial resistance rates in a seven-bed medical--surgical ICU in Rio de Janeiro, Brazil and comparison with ICARE (CDC-USA) rates. All isolates were responsible for hospital-acquired infections. The National Committee for Clinical Laboratory Standards were used for the minimum inhibitory concentration, or zone diameter testing standards reporting susceptible, intermediate, or resistant organisms.

Results
=======

The rates of antimicrobial resistance were: methicillin-resistant *S. aureus*, 50% RJ-ICU vs 68% USA-ICU (*P*= 0.165); quinolone-resistant *P. aeruginosa*, 80% RJ-ICU vs 52% USA-ICU (*P*\< 0.0001); imipenem-resistant *P. aeruginosa*, 49% RJ-ICU vs 38% USA-ICU; ceftazidime-resistant *P. aeruginosa*, 32% RJ-ICU vs 24% USA-ICU (*P*= 0.15); third cephalosporin-resistant *Enterobacter*spp., 60% RJ-ICU vs 47% USA-ICU (*P*= 0.412); and third cephalosporin-resistant *K. pneumoniae*, 30% RJ-ICU vs 21% EUA-ICU (*P*= 0.329).
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Conclusion
==========

Quinolone-resistant *P. aeruginosa*was significantly higher in the RJ-ICU than in the USA-ICU. We speculate that this difference could be related to different antimicrobial use or patient severity.
